Resultats globals: 39 registres trobats en 0.01 segons.
Articles, 34 registres trobats
Documents de recerca, 5 registres trobats
Articles 34 registres trobats  1 - 10següentfinal  anar al registre:
1.
5 p, 705.6 KB Cefepime Dosing Requirements in Elderly Patients Attended in the Emergency Rooms / Ruiz Ramos, Jesus (Institut d'Investigació Biomèdica Sant Pau) ; Herrera, Sergio (Institut d'Investigació Biomèdica Sant Pau) ; López-Vinardell, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Juanes-Borrego, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Puig Campmany, Mireia (Institut d'Investigació Biomèdica Sant Pau) ; Mangues, Ma Antonia (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
This study aimed to assess the probability of reaching an adequate pharmacokinetic/pharmacodynamic (pK/pD) index for different cefepime dosages in frail patients with bacteremia treated in the emergency room. [...]
2022 - 10.1177/15593258221078393
Dose-Response, Vol. 20 Núm. 1 (31 2022)  
2.
22 p, 4.5 MB Machine Learning Models for Predicting Personalized Tacrolimus Stable Dosages in Pediatric Renal Transplant Patients / Sánchez-Herrero, Sergio (Universitat Oberta de Catalunya. Departament d'Informàtica, Multimèdia i Telecomunicació.) ; Calvet Liñan, Laura (Universitat Autònoma de Barcelona. Departament de Telecomunicació i Enginyeria de Sistemes) ; Juan, Ángel A (Universitat Politècnica de València. Centre de Recerca en Gestió i Enginyeria de la Producció)
Tacrolimus, characterized by a narrow therapeutic index, significant toxicity, adverse effects, and interindividual variability, necessitates frequent therapeutic drug monitoring and dose adjustments in renal transplant recipients. [...]
2023 - 10.3390/biomedinformatics3040057
BioMedInformatics, Vol. 3, Issue 4 (December 2023) , p. 926-947  
3.
10 p, 5.6 MB PITB : A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties / Pinheiro, Francisca (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Varejão, Nathalia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Sánchez-Morales, Adrià (Universitat Autònoma de Barcelona. Departament de Química) ; Bezerra, Filipa (Instituto de Ciências Biomédicas de Abel Salazar (Porto, Portugal)) ; Navarro, Susanna (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Velázquez-Campoy, Adrian (Universidad de Zaragoza) ; Busqué Sánchez, Félix (Universitat Autònoma de Barcelona. Departament de Química) ; Almeida, Maria Rosário (Instituto de Ciências Biomédicas de Abel Salazar (Porto, Portugal)) ; Alibes, Ramón (Universitat Autònoma de Barcelona. Departament de Química) ; Reverter i Cendrós, David (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Pallarès i Goitiz, Irantzu (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Ventura, Salvador (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
The aggregation of wild-type transthyretin (TTR) and over 130 genetic TTR variants underlies a group of lethal disorders named TTR amyloidosis (ATTR). TTR chemical chaperones are molecules that hold great promise to modify the course of ATTR progression. [...]
2023 - 10.1016/j.ejmech.2023.115837
European Journal of Medicinal Chemistry, Vol. 261 (may 2023) , p. 115837  
4.
13 p, 1.6 MB The development of highly dense highly protected surfactant ionizable lipid RNA loaded nanoparticles / González-Rioja, Ramon (Institut Català de Nanociència i Nanotecnologia) ; Salazar Montoya, Vivian Angélica (Institut Català de Nanociència i Nanotecnologia) ; Bastús, Neus G (Institut Català de Nanociència i Nanotecnologia) ; Puntes, Víctor (Hospital Universitari Vall d'Hebron. Institut de Recerca)
The long quest for efficient drug administration has been looking for a universal carrier that can precisely transport traditional drugs, new genomic and proteic therapeutic agents. Today, researchers have found conditions to overcome the two main drug delivery dilemmas. [...]
2023 - 10.3389/fimmu.2023.1129296
Frontiers in immunology, Vol. 14 (February 2023) , art. 1129296  
5.
15 p, 1.9 MB GC-MS/MS Determination of Synthetic Cathinones : 4-chloromethcathinone, N-ethyl Pentedrone, and N-ethyl Hexedrone in Oral Fluid and Sweat of Consumers under Controlled Administration: Pilot Study / Nuñez-Montero, Melani (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Lombroni, Claudia (Univesità degli Studi di Torino) ; Maida, Nunzia La (Istituto Superiore di Sanità) ; Rotolo, Maria Concetta (Istituto Superiore di Sanità) ; Pichini, Simona (Istituto Superiore di Sanità) ; Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Hladun, Olga (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ventura, Mireia (Associació Benestar i Desenvolupament) ; Poyatos, Lourdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pérez-Mañá, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Marchei, Emilia (Istituto Superiore di Sanità) ; Universitat Autònoma de Barcelona
This study presents a validated GC-MS/MS method for the detection and quantification of 4-chloromethcathinone or clephedrone (4-CMC), N-ethyl Pentedrone (NEP), and N-ethyl Hexedrone (NEH, also named HEXEN) in oral fluid and sweat and verifies its feasibility in determining human oral fluid concentrations and pharmacokinetics following the administration of 100 mg of 4-CMC orally and 30 mg of NEP and NEH intranasally. [...]
2023 - 10.3390/ijms24119387
International journal of molecular sciences, Vol. 24 (may 2023)  
6.
12 p, 983.1 KB Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients : the better study / Fernandez Rivera, Constantino (Complejo Hospitalario Universitario de A Coruña) ; Calvo Rodríguez, María (Complejo Hospitalario Universitario de A Coruña) ; Poveda, José Luís (Hospital Universitari i Politècnic La Fe (València)) ; Pascual, Julio (Pascual Santos) (Institut Hospital del Mar d'Investigacions Mèdiques) ; Crespo, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Gomez, Gonzalo (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Cabello Pelegrin, Sheila (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Paul, Javier (Hospital Universitario Miguel Servet (Saragossa)) ; Lauzurica, Ricardo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Perez Mir, Mònica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Moreso, Francesc (Hospital Universitari Vall d'Hebron) ; Perelló, Manel (Hospital Universitari Vall d'Hebron) ; Andres, Amado (Hospital 12 de Octubre (Madrid)) ; González, Esther (Hospital 12 de Octubre (Madrid)) ; Fernandez, Ana (Hospital Universitario Ramón y Cajal (Madrid)) ; Mendiluce, Alicia (Hospital Universitario Clínico de Valladolid) ; Fernández Carbajo, Beatriz (Hospital Universitario Clínico de Valladolid) ; Sanchez Fructuoso, Ana (Hospital Universitario Clínico San Carlos (Madrid)) ; Calvo, Natividad (Hospital Universitario Clínico San Carlos (Madrid)) ; Suarez, Alejandro (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Bernal Blanco, Gabriel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Osuna, Antonio (Hospital Universitario Virgen de las Nieves (Granada)) ; Ruiz-Fuentes, M. Carmen (Hospital Universitario Virgen de las Nieves (Granada)) ; Melilli, Edoardo (Hospital Universitari de Bellvitge) ; Montero, Nuria (Hospital Universitari de Bellvitge) ; Ramos, Ana (Hospital Universitario Fundación Jiménez Díaz) ; Fernández, Beatriz (Hospital Universitario Fundación Jiménez Díaz) ; López, Verónica (Universidad de Málaga) ; Hernandez, Domingo (Universidad de Málaga) ; Universitat Autònoma de Barcelona
Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. [...]
2021 - 10.1111/ctr.14550
Clinical Transplantation, Vol. 36 (december 2021)  
7.
13 p, 819.4 KB Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans / Poyatos, Lourdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Lo Faro, Alfredo Fabrizio (Università Politecnica delle Marche) ; Berardinelli, Diletta (Università Politecnica delle Marche) ; Sprega, Giorgia (Università Politecnica delle Marche) ; Malaca, Sara (Università Politecnica delle Marche) ; Pichini, Simona (Istituto Superiore di Sanità) ; Huestis, Marilyn A. (Thomas Jefferson University) ; Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pérez-Mañá, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Busardo, Francesco Paolo (Università Politecnica delle Marche) ; Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
The aim of this study is to define, for the first time, human methylone and HMMC plasma pharmacokinetics following controlled administration of 50-200 mg methylone to 12 male volunteers. A new LC-MS/MS method was validated to quantify methylone, MDMA, and their metabolites in plasma. [...]
2022 - 10.3390/ijms232314636
International journal of molecular sciences, Vol. 23 (november 2022)  
8.
9 p, 771.4 KB Sweat Testing for the Detection of Methylone after Controlled Administrations in Humans / Di Giorgi, Alessandro (Università Politecnica delle Marche) ; Sprega, Giorgia (Università Politecnica delle Marche) ; Poyatos, Lourdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pérez-Mañá, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Di Trana, Annagiulia (Istituto Superiore di Sanità) ; Varì, Maria Rosaria (Instituto Superiore di Sanità) ; Busardo, Francesco Paolo (Università Politecnica delle Marche) ; Pichini, Simona (Istituto Superiore di Sanità) ; Zaami, Simona (Università La Sapienza) ; Lo Faro, Alfredo Fabrizio (Università Politecnica delle Marche) ; Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
The aim of this study was to determine the excretion of methylone and its metabolites in sweat following the ingestion of increasing controlled doses of 50, 100, 150 and 200 mg of methylone to twelve healthy volunteers involved in a clinical trial. [...]
2023 - 10.3390/ijms24087395
International journal of molecular sciences, Vol. 24 (april 2023)  
9.
12 p, 1.5 MB Usefulness of Oral Fluid for Measurement of Methylone and Its Metabolites : Correlation with Plasma Drug Concentrations and the Effect of Oral Fluid pH / Sprega, Giorgia (Università Politecnica delle Marche) ; Di Giorgi, Alessandro (Università Politecnica delle Marche) ; Poyatos, Lourdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pérez-Mañá, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tini, Anastasio (Università Politecnica delle Marche) ; Pichini, Simona (Istituto Superiore di Sanità) ; Busardo, Francesco Paolo (Università Politecnica delle Marche) ; Lo Faro, Alfredo Fabrizio (Università Politecnica delle Marche) ; Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
The aim of this study was to investigate methylone and its metabolites concentration in oral fluid following controlled increasing doses, focusing on the effect of oral fluid pH. Samples were obtained from a clinical trial where twelve healthy volunteers participated after ingestion of 50, 100, 150 and 200 mg of methylone. [...]
2023 - 10.3390/metabo13040468
Metabolites, Vol. 13 (march 2023)  
10.
14 p, 1.9 MB Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients : a randomised controlled trial / Chastre, Jean (Service de Médecine Intensive Réanimation. Institut de Cardiologie. Groupe Hospitalier Pitié-Salpêtrière. Assistance Publique-Hôpitaux de Paris. Sorbonne University) ; François, Bruno (Réanimation Polyvalente and Inserm CIC 1435 & UMR 1092. CHU) ; Bourgeois, Marc (AZ Sint-Jan Brugge-Oostende AV) ; Komnos, Apostolos (General Hospital of Larissa) ; Ferrer, Ricard (Hospital Universitari Vall d'Hebron) ; Rahav, Galia (Chaim Sheba Medical Center. Sackler School of Medicine. Tel Aviv University) ; De Schryver, Nicolas (Clinique Saint-Pierre) ; Lepape, Alain (Hospices Civils de Lyon Hôpital Lyon Sud) ; Koksal, Iftihar (Faculty of Medicine. Trabzon and Acibadem University Faculty of Medicine. Karadeniz Technical University) ; Luyt, Charles-Edouard (Service de Médecine Intensive Réanimation. Institut de Cardiologie. Groupe Hospitalier Pitié-Salpêtrière. Assistance Publique-Hôpitaux de Paris. Sorbonne University) ; Sánchez-García, Miguel (Hospital Clínico San Carlos. Unidad de Cuidados Intensivos) ; Torres, Antoni (Hospital Clínic i Provincial de Barcelona. Servei de Pneumologia) ; Eggimann, Philippe (Department of Locomotor Apparatus. Centre Hospitalier Universitaire Vaudois CHUV) ; Koulenti, Despoina (2nd Critical Care Department. Attikon University Hospital. National and Kapodistrian. University of Athens) ; Holland, Thomas L. (Duke Clinical Research Institute) ; Ali, Omar (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Shoemaker, Kathryn (Respiratory and Immunology. BioPharmaceuticals R&D. AstraZeneca) ; Ren, Pin (Respiratory and Immunology. BioPharmaceuticals R&D. AstraZeneca) ; Sauser, Julien (Infection Control Program. Faculty of Medicine. Geneva University Hospitals) ; Ruzin, Alexey (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Tabor, David E. (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Akhgar, Ahmad (Clinical Pharmacology and Quantitative Pharmacology. Clinical Pharmacology and Safety Sciences. BioPharmaceuticals R&D. AstraZeneca) ; Wu, Yuling (Clinical Pharmacology and Quantitative Pharmacology. Clinical Pharmacology and Safety Sciences. BioPharmaceuticals R&D. AstraZeneca) ; Jiang, Yu (Clinical Pharmacology and Quantitative Pharmacology. Clinical Pharmacology and Safety Sciences. BioPharmaceuticals R&D. AstraZeneca) ; DiGiandomenico, Antonio (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Colbert, Susan (Oncology. US SM&M. AstraZeneca) ; Vandamme, Drieke (Inserm CIC 1435. CHU) ; Coenjaerts, Frank (University Medical Center Utrecht) ; Malhotra-Kumar, Surbhi (University of Antwerp. Laboratory of Medical Microbiology) ; Timbermont, Leen (University of Antwerp. Laboratory of Medical Microbiology) ; Oliver, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Barraud, Olivier (INSERM U1092. Centre Hospitalier Universitaire de Limoges. Université Limoges) ; Bellamy, Terramika (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Bonten, Marc (Julius Center for Health Science and Primary Care. University Medical Center Utrecht. Utrecht University) ; Goossens, Herman (Laboratory of Medical Microbiology. Vaccine and Infectious Disease Institute. University of Antwerp) ; Reisner, Colin (DevPro Biopharma) ; Esser, Mark T. (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Jafri, Hasan S. (Late-Stage Development. Respiratory and Immunology. BioPharmaceuticals R&D. AstraZeneca) ; Joannidis, Michael ; Klimscha, Walter ; De Waele, Elisabeth ; Devriendt, Jacques ; Huberlant, Vincent ; Depuydt, Pieter ; Van Boxstael, Sam ; Peric, Mladen ; Kopic, Jasminka ; Hanauer, Michal ; Hruby, Tomas ; Sramek, Vladimir ; Svoboda, Petr ; Vymazal, Tomas ; Novacek, Martin ; Annane, Djillali ; Mira, Jean-Paul ; Souweine, Bertrand ; Dequin, Pierre-François ; Meziani, Ferhat ; Stephan, François ; Nseir, Saad ; Gibot, Sebastien ; Schwebel, Carole ; Plantefeve, Gaetan ; Diehl, Jean-Luc ; Richard, Christian ; Lamer, Christian ; Klouche, Kada ; Jaber, Samir ; Zakynthinos, Epaminondas ; Filntisis, Georgios ; Zakynthinos, Spyros ; Koutsoukou, Antonia ; Saroglou, Georgios ; Nikolaou, Charikleia ; Vlachogianni, Glykeria ; Pnevmatikos, Ioannis ; Mandragos, Konstantinos ; Kremer, Ildiko ; Rozgonyi, Zsolt Dezso ; Marjanek, Zsuzsa ; Martin-Loeches, Ignacio ; Singer, Pierre ; Van Heerden, Vernon ; Carmeli, Yehuda ; Povoa, Pedro ; AlvarezSeoane, Antonio ; Moura, Pedro ; Gonzalez, Filipe ; Ramirez, Paula ; Torres Marti, Antonio ; Ferrer Roca, Ricard ; Oteiza, Lorena ; Escudero, Dolores ; Piacentini, Enrique ; Vera-Artazcoz, Paula (Institut d'Investigació Biomèdica Sant Pau) ; Tamayo, Luis ; Gonzalez Gallego, Miguel Angel ; Suberviola Canas, Borja ; Figueira, Iglesias ; Leon, Rafael ; Korten, Volkan ; Akova, Murat ; Wyncoll, Duncan ; Whitehouse, Tony ; Hopkins, Phil ; Sim, Malcolm ; Golan, Yoav ; Zervos, Marcus ; Vazquez, Jose ; Cherabuddi, Kartikeya ; Smulian, George ; Rouphael, Nadine ; Welker, James ; Sims, Mathew ; Van Duin, David ; McCarthy, Todd ; Polk, Christopher
Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects. [...]
2022 - 10.1186/s13054-022-04204-9
Critical Care, Vol. 26 Núm. 1 (december 2022) , p. 355  

Articles : 34 registres trobats   1 - 10següentfinal  anar al registre:
Documents de recerca 5 registres trobats  
1.
3.9 MB Efectos agudos asociados al consumo de metilona / Poyatos Blanco, Lourdes ; Pérez Mañá, Clara, dir.
La metilona (3,4-metilenedioximetcatinona), també anomenada "MDMC", "bk-MDMA" o "M1", és una catinona sintètica popularitzada inicialment com una alternativa legal de les drogues clàssiques. Els consumidors comparen els seus efectes farmacològics amb els de la 3,4-metilenedioximetanfetamina (èxtasi o MDMA), amb la qual comparteix estructures químiques similars. [...]
La metilona (3,4-metilenedioximetcatinona), también denominada "MDMC", "bk-MDMA" o "M1", es una catinona sintética popularizada inicialmente como una alternativa legal de las drogas clásicas. Los consumidores comparan sus efectos farmacológicos con los de la 3,4-metilenedioximetanfetamina (éxtasis o MDMA), con la que comparte similitud en su estructura química. [...]
Methylone (3,4-methylenedioxymethcathinone), also called "MDMC", "bk-MDMA" or "M1", is a synthetic cathinone initially popularized as a legal alternative to classic drugs. Users compare its pharmacological effects with those of 3,4-methylenedioxymethamphetamine (ecstasy or MDMA), which could be related to the similarity in their chemical structures. [...]
Universitat Autònoma de Barcelona. Programa de Doctorat en Farmacologia.

2023  
2.
10.5 MB Evaluation of different therapeutic options against extensively drug-resistant (XDR) Pseudomonas aeruginosa, including high-risk clones, using different in vitro pharmacokinetic/pharmacodynamic (PK/PD) models / Domene, Sandra ; Horcajada, Juan Pablo, dir. ; Milagros Montero, Maria, dir. ; Navarro Risueño, Ferran, dir.
L'ús indiscriminat d'antibiòtics ha contribuït a l'aparició i propagació de Pseudomonas aeruginosa extremadament resistent als antibiòtics (XDR). L'augment de soques XDR compromet seriosament les opcions de tractament amb antibiòtics i condueix a taxes més altes de morbiditat i mortalitat entre els pacients amb infeccions per P. [...]
El uso indiscriminado de antibióticos ha contribuido a la aparición y propagación de Pseudomonas aeruginosa extremadamente resistente a los antibióticos (XDR). El aumento de las cepas XDR compromete seriamente las opciones de tratamiento con antibióticos y conduce a tasas más altas de morbilidad y mortalidad entre los pacientes con infecciones por P. [...]
The indiscriminate use of antibiotics has contributed to the emergence and spread of extensively drug-resistant (XDR) Pseudomonas aeruginosa. The increase in XDR strains seriously compromises antibiotic treatment options and led to higher morbidity and mortality rates among patients with P. [...]

2023  
3.
172 p, 13.5 MB Estudi farmacològic del Carprofen ex vivo i in vivo en l'espècie porcina / Gómez Segura, Lídia ; Gimeno Sandig, Alvaro, dir. ; Parra Coca, Alexander, dir. ; Cuenca Valera, Rafaela, dir.
El Carprofè s'utilitza com a agent antiinflamatori, analgèsic i antipirètic. Pertany a la família de medicaments antiinflamatoris no esteroideus. S'utilitza en medicina veterinària en nombroses espècies, tot i així està molt poc estudiat el seu ús en l'espècie porcina. [...]
El Carprofè utiliza como agente antiinflamatorio, analgésico y antipirético. Pertenece a la familia de medicamentos antiinflamatorios no esteroideos. Se utiliza en medicina veterinaria en numerosas especies, aún así está muy poco estudiado su uso en la especie porcina. [...]
Carprofen is used as an anti-inflammatory, analgesic and antipyretic agent. It belongs to the family of non-steroidal anti-inflammatory drugs. It is used in veterinary medicine in many species, although its use in the porcine species is very little studied. [...]

2021  
4.
201 p, 9.4 MB Relevancia clínica de la monitorización de niveles de Linezolid en el paciente crítico / Muñoz Bermúdez, Rosana ; Álvarez Lerma, Francisco, dir. ; Grau, Santiago, dir. ; Pedro-Botet, Juan, dir.
Linezolid és un antibiòtic ampliament utilitzat en pacients crítics pel tractament d'infeccions en les que es coneix o se sospita la presència de cocos Gram positius (CGP) resistents a meticil·lina o vancomicina. [...]
Linezolid es un antibiótico ampliamente utilizado en pacientes críticos para el tratamiento de infecciones en las que se conoce o se sospecha la presencia de cocos Gram positivos (CGP) resistentes a meticilina o vancomicina. [...]
Linezolid is an antibiotic widely used in critically ill patients for the treatment of infections in which the presence of Gram-positive cocci (PGC) resistant to methicillin or vancomycin is known or suspected. [...]

2021  
5.
1 p, 2.1 MB Immunoliposomes state of the art : pharmacokinetics of a novel drug delivery system for cancer treatment / García Pagès, Esther ; Vivas Sabido, Nuria María, dir. (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Universitat Autònoma de Barcelona. Facultat de Biociències
2015
Grau en Ciències Biomèdiques [832]  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.